Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter
9%
Acinetobacter Baumannii
39%
Acute Hepatitis C
5%
Amoxicillin
9%
Ampicillin
9%
Antimicrobial Resistance
41%
Aspergillus
13%
Beet
39%
Beetroot
39%
Candida
26%
Candida Albicans
26%
Candidemia
26%
Carbapenem Derivative
9%
Chronic Hepatitis C
11%
Chronic Liver Disease
5%
Clavulanic Acid
9%
Comorbidity
5%
Cotrimoxazole
9%
Cytochrome C
15%
Cytokeratin 18
19%
Elimination
47%
Enterobacter
9%
Enzyme-Linked Immunosorbent Assay
7%
Ertapenem
19%
Experimental Rat
13%
Extended Spectrum Beta Lactamase
19%
Fungal Isolates
39%
Geotrichum
13%
Glutamic Acid
13%
Gram Negative Bacterium
39%
Haemophilia A
39%
Hepatitis C
100%
Hepatitis C Virus
89%
HIV
43%
Hyaluronic Acid
27%
Infectious Agent
13%
Klebsiella
19%
Leukocyte Antigen
26%
Liver Cirrhosis
9%
Liver Fibrosis
39%
Meropenem
12%
Mixed Infection
39%
Mycosis
13%
Narcotic Agent
17%
Pathogen Clearance
39%
Penicillin
9%
Prevalence
92%
Virus Antibody
44%
Virus Hepatitis
21%
Wistar Rat
13%
Medicine and Dentistry
Acinetobacter
9%
Acinetobacter Baumannii
39%
Acinetobacter Infection
5%
Amikacin
5%
Amoxicillin/Clavulanic Acid
9%
Ampicillin
9%
Antibiogram
7%
Antibiotic Resistance
41%
Aspergillus
19%
Assisted Living
39%
Bloodstream Infection
5%
Candidemia
39%
Carbapenem Derivative
9%
Central Venous Catheter
5%
Ciprofloxacin
5%
Colistimethate
5%
Cytochrome C
17%
Enzyme Linked Immunosorbent Assay
8%
Ertapenem
19%
Escherichia
9%
Extended Spectrum Beta Lactamase
19%
Geotrichum
19%
Gram-Negative Bacteria
39%
Hand Hygiene
5%
Hepatitis C
43%
Hepatitis C Virus
39%
Hepatitis Virus
21%
Hepatocyte
8%
High Risk Population
8%
Human Immunodeficiency Virus
43%
Imipenem
5%
Infection Control
20%
Intensive Care
19%
Keratin 18
21%
Klebsiella
19%
Liver Fibrosis
39%
Lung Lavage
19%
Meropenem
12%
Mixed Infection
39%
Mycosis
19%
Pathogen
19%
Patient with Human Immunodeficiency Virus
39%
Penicillin
9%
Prevalence
88%
Programmed Cell Death
39%
Sputum
19%
Trimethoprim/Sulfamethoxazole
9%
Unprotected Sex
8%
Virus Antibody
39%